SCHEMBL20072095

SCHEMBL20072095

Cc1cc(C)nc(N2c3ccc(C(C)(C)C)cc3N(c3nc(C)cc(C)n3)C2C2N(c3nc(C)cc(C)n3)c3ccc(C(C)(C)C)cc3N2c2nc(C)cc(C)n2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
USP2 O75604 1/20 0.36
GBA1 P04062 1/20 0.36
ALDH1A1 P00352 6/20 0.36
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
HTT P42858 1/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20681870 0.85 HCRTR1 (0.36) HCRTR1HCRTR2MEN1KMT2AHPGD
SCHEMBL20071768 0.83 SCN10A (0.33) HCRTR1HCRTR2MEN1KMT2AHPGD
SCHEMBL20072096 0.81 KDM4E (0.42) HCRTR1HCRTR2MEN1KMT2AHPGD
SCHEMBL20062926 0.79 HCRTR1 (0.39) HCRTR1HCRTR2MEN1KMT2AHPGD
SCHEMBL20681894 0.78 ALDH1A1 (0.33) MEN1KMT2AHPGDHSD17B10ALDH1A1
SCHEMBL20681895 0.77 USP2 (0.40) HCRTR1HCRTR2MEN1KMT2AKDM4E
SCHEMBL20681831 0.75 SCN10A (0.33) HCRTR1HCRTR2HPGDHSD17B10ALDH1A1
SCHEMBL20072003 0.74 TRPV1 (0.31) MEN1KMT2AHTTSCN10AKCNH2
SCHEMBL18911705 0.73 MAPT (0.33) MEN1KMT2AHPGDKDM4EHSD17B10
SCHEMBL20681889 0.73 KIF11 (0.43) HPGDHSD17B10NPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10541260-B2 Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus CANON KABUSHIKI KAISHA (JP) 2020-01-21 US disclosed
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same CANON KABUSHIKI KAISHA (JP) 2019-01-29 US disclosed
US-20180108691-A1 ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS CANON KABUSHIKI KAISHA (JP) 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10193084-B2 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same BRD1, DRD1, NR2E3 HCRTR1 367/4885HCRTR2 205/4885MEN1 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.